妊娠合并糖尿病母胎医学研究北京市重点实验室于2015年经北京市科委正是批准成立，依托北京大学第一医院建设。实验室总体定位：立足北京需求，辐射京津冀发展，瞄准国际前沿，研究妊娠合并糖尿病及相关疾病发病机理，建立临床规范化产前，产时及产后干预措施及管理规范，建立多学科会诊平台，全面提高胎儿宫内疾病的诊治水平。大力普及妊娠糖尿病相关知识，提高患者就医诊治的依从性，通过合理预防和病前干预降低发病率。建立相关技术平台和基础设施，实现开放共享。培养本领域优秀人才，建立完善的科研及临床梯队。为北京市的产科规范管理和发展提供支持和保障。

　　在妊娠期合并糖尿病的综合规范管理基础上，建立妊娠合并糖尿病规范化临床队列，进行统一的临床信息和样本的系统化网络化管理，制定早期预防策略，减少母儿近远期不良妊娠结局：

　　1.1.1从遗传易感基因及其多态性、表观遗传学机制等方面，深入探讨妊娠期合并糖尿病影响母儿结局的发病机制，并通过临床随机对照研究制定妊娠合并糖尿病的早期干预策略，降低母儿近远期不良结局的发生率；

　　1.1.2基于妊娠期合并糖尿病最常见的母体合并症——子痫前期发病机制的研究，筛选早期生物标记物和干预候选靶点，并通过大样本临床随机对照研究进行验证，实现子痫前期早期的临床预测并早期干预，改善母儿结局；

　　1.1.3对妊娠合并糖尿病常见的胎儿结构异常——胎儿泌尿系统结构异常、神经系统结构异常，进行系统的产前筛查和诊断，有针对性地进行多学科规范管理，减少出生缺陷的发生；

　　具体研究方向为：

　　研究糖尿病诱发子痫前期发病机制，筛选早期生物标记物和干预候选靶点

　　通过大样本临床随机对照研究，实现子痫前期早期的临床预测并早期干预

　　糖尿病致胎儿结构及代谢异常的分子机制研究及干预策略

 

　　妊娠合并糖尿病母胎医学研究北京市重点实验室，科研队伍实力雄厚，人员稳定，杨慧霞教授担任实验室主任，研究人员包括教授、研究员、副教授、副主任医师和专业技术人员等研究人员共47名,其中拥有副高以上职称的人员共21名，约29人拥有博士学位及海外留学经历，并有经验丰富的技术队伍。目前有在站博士后1名，在读研究生43人,其中硕士生28人，博士生15人。经培训人员或毕业的研究生多已成为兄弟医院及各省市妇产科科学界的学术带头人或科室骨干。

　　现有实验室面积约1550平方米，科研设备固定资产超过1400万元，通过三年的软件和硬件建设，逐步形成临床数据和标本数据的有机整合的临床队列数据管理系统。

　　基金项目

　　依托本实验室平台,申请并新获批妊娠疾病相关13.5 重点专项4项,总计经费1360万元，国家自然科学基金项目4项，部位级项目8项，国际项目1项

　　总计经费2260万元

　　获奖

　　2015年杨慧霞等获得妇幼健康科学技术成果一等奖

　　杨慧霞教授入选2017年度科技北京百名领军人才培养工程

　　闫婕获北京市优秀人才培养资助（青年拔尖个人）

　　杨慧霞等获得2017中国妇幼健康技术大会科技成果一等奖

　　孙瑜等获得`2017中国妇幼健康技术大会科技成果二等奖

 

　　依托妊娠合并糖尿病母胎医学研究北京市重点实验室，发表论文10篇；形成行业共识和指南以糖尿病母胎医学研究北京市重点实验室为依托，利用项目建设的契机形成多项行业规范；申请专利5项，授权专利3项。构建全国产科危重病科研协作联盟；开展适宜技术的推广及多中心协同诊疗；建立产科特色队列人群和生物样本库

　　

　　机构负责人：杨慧霞

　　联系人：金鸿雁

　　邮箱：maggijhy@163.com

　　电话：83573859

　　地址：北京市西城区西安门大街1号

　　

　　

　　Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus

　　Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus（GDM）,which belongs to Peking university First Hospital, was founded in 2015 authorized by Beijing Municipal Science and Technology Commission. The overall orientation of key lab is based on the following aspects: satisfying the needs of Beijing, generating a spillover effect to Tianjin municipalities and Hebei Province, aiming at the international front which focus on the mechanism of GDM and related diseases, establishing a standardized operation and interference for prenatal, perinatal and postnatal,  setting up a multi-disciplinary consultation platform for treating fetal intrauterine disease, popularizing knowledge of GDM in order to lowing the incidence of the GDM by effective prevention and intervention, building  infrastructure and technologic platform as well as setting up sharing mechanism, cultivating excellent obstetrics talents, the final aim is to support the development of Beijing on obstetrics.

　　Establishing standardized GDM clinical cohort based on system management and network of clinical and biorepository data. Formulation of early prevention strategies to reduce adverse pregnancy outcomes in mother and child.

　　1.1.1

　　Identifying the genetic susceptibility gene and its polymorphism and epigenetic mechanisms, keep on studying of the pathogenesis of perinatal outcomes accompany with GDM, and to develop early intervention strategies of GDM through randomized controlled clinical study, reduce the incidence of maternal and fetal long-term adverse outcomes

　　1.1.2 Identifying the pathogenesis of preeclampsia ,which is the most common pregnancy complication of GDM, based on the screening of early biomarkers and intervention targets , verifying these biomarker through large sample randomized controlled clinical study, implementation early clinical prediction and early intervention of preeclampsia, improve the outcome of maternal and offspring's;

　　1.1.3 Systematic prenatal screening and diagnosis of fetal structural abnormalities, fetal urinary system structure abnormalities and nervous system structure abnormalities are carried out for GDM patient. Targeted multidisciplinary management should be carried out to reduce birth defects.

　　Research Directions：

　　screening early biomarkers and intervention targets of preeclampsia accompany with GDM.

　　Carrying on clinical prediction and early intervention of early preeclampsia through large sample randomized controlled trials

　　Indentifying the molecular mechanism and intervention strategy of fetal structure and metabolic abnormalities induced by diabetes

　　Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus（GDM）leading by Professor Yanghuixia1,has a stable personnel and strong scientific research team. Researchers include professors, researchers, associate professors, deputy chief physicians and professional technicians. A total of 47 researchers, including 21  professor and associated professor, and 29 people have doctoral degrees and overseas study experience. There are 1 postdoctoral candidates at the station and 43 graduate students, including 28 master students and 15 doctoral students. Most of the trainees or graduate students have become the academic leaders or the backbone of the Department of Obstetrics and gynecology in the brothers hospitals

　　The existing laboratory area is about 1550 square meters, and the fixed assets of research equipment are over 14 million yuan. Through the construction of software and hardware for three years, the clinical cohort management system is gradually established and integrated with clinical data and specimen data.

　　Relying on our laboratory platform, we acquired 4 key special projects related to pregnancy diseases, with a total cost of 13 million 600 thousand yuan, 4 items from the National Natural Science Foundation, 8 items from Provincial and ministerial projects , and 1 items from world diabetes foundation . Total amount of new research funds of 22 million 600 thousand yuan.

　　Base on work of Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus, a number of consensus and guidelines was made, 5 patents are applied and 3 patents are authorized. Constructed a National Alliance for scientific research and cooperation on critical diseases in obstetrics. Promoted suitable technology and multi center cooperative diagnosis and treatment. Established  a cohort of obstetric features and a biological sample library.

　　

　　Director: Huixia Yang

　　Contact：Hongyan Jin

　　E-mail：yanghuixia@bjmu.edu.cn；maggijhy@163.com

　　Tel：83573859

　　Address：Peking University First Hospital